Drugs / Psilocin
Psilocin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06035900 | Jun → Jul 2023 | — | Lobe Sciences Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06898606 | Sep 2024 → Aug 2026 overdue | depressive disorder | Federal University of Latin American Integration | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05317689 Comparator | May 2022 → Jan 2025 overdue | — | University of California, San Francisco | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Psilocin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06035900 ↗ |
| Known as | 4-ho-dmt | ChEMBL registry synonym — accepted as the source's own label CHEMBL65547 ↗ |
| Known as | Deupsilocina | ChEMBL registry synonym — accepted as the source's own label CHEMBL65547 ↗ |
| Known as | Deupsilocine | ChEMBL registry synonym — accepted as the source's own label CHEMBL65547 ↗ |
| Known as | Psilocyn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06898606 ↗ |
| Modality | Small molecule | — CHEMBL65547 ↗ |
| Route | Oral | “17.5mg oral psilocin with psychological support and physiological monitoring” NCT05317689 ↗ |